Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study

Background and Objectives: Remdesivir (RDV) is the first antiviral agent approved in Japan for the treatment of coronavirus disease 2019 (COVID-19). The aim of our study was to assess the efficacy and safety of RDV treatment in mildly to moderately ill patients with COVID-19. Materials and Methods:...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyazaki, Motoyasu, Yanagida, Ryoko, Nakashima, Akio, Matsuo, Koichi, Moriwaki, Norihiro, Uchiyama, Masanobu, Yamada, Yota, Hirata, Hitomi, Kushima, Hisako, Kinoshita, Yoshiaki, Ishii, Hiroshi, Imakyure, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414265/
https://www.ncbi.nlm.nih.gov/pubmed/36013474
http://dx.doi.org/10.3390/medicina58081007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414265/
https://www.ncbi.nlm.nih.gov/pubmed/36013474
http://dx.doi.org/10.3390/medicina58081007

Ejemplares similares